1242. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
作者: Eliano Pio Navarese.;Michalina Kolodziejczak.;Volker Schulze.;Paul A Gurbel.;Udaya Tantry.;Yingfeng Lin.;Maximilian Brockmeyer.;David E Kandzari.;Julia M Kubica.;Ralph B D'Agostino.;Jacek Kubica.;Massimo Volpe.;Stefan Agewall.;Dean J Kereiakes.;Malte Kelm.
来源: Ann Intern Med. 2015年163卷1期40-51页
Guidelines recommend statins as first-line therapy for dyslipidemia. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new lipid-lowering approach.
1243. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
作者: Stefan Zeuzem.;Reem Ghalib.;K Rajender Reddy.;Paul J Pockros.;Ziv Ben Ari.;Yue Zhao.;Deborah D Brown.;Shuyan Wan.;Mark J DiNubile.;Bach-Yen Nguyen.;Michael N Robertson.;Janice Wahl.;Eliav Barr.;Joan R Butterton.
来源: Ann Intern Med. 2015年163卷1期1-13页
Novel interferon- and ribavirin-free regimens are needed to treat hepatitis C virus (HCV) infection.
|